These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 18654064

  • 1. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 2. Diabesity: therapeutic options.
    Colagiuri S.
    Diabetes Obes Metab; 2010 Jun; 12(6):463-73. PubMed ID: 20518802
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F.
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [Abstract] [Full Text] [Related]

  • 4. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K.
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [Abstract] [Full Text] [Related]

  • 5. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
    Bonora E.
    Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
    [Abstract] [Full Text] [Related]

  • 6. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Aug; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 7. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S.
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [Abstract] [Full Text] [Related]

  • 8. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH.
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [Abstract] [Full Text] [Related]

  • 9. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
    Peters AL.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ.
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [Abstract] [Full Text] [Related]

  • 11. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
    Rotella CM, Pala L.
    Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 13. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [Abstract] [Full Text] [Related]

  • 14. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.
    Cefalu WT, Richards RJ, Melendez-Ramirez LY.
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S39-47. PubMed ID: 19952302
    [Abstract] [Full Text] [Related]

  • 15. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL.
    Diabetes Educ; 2008 Dec; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [Abstract] [Full Text] [Related]

  • 16. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 17. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 18. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ, Conner C.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [Abstract] [Full Text] [Related]

  • 19. Weight beneficial treatments for type 2 diabetes.
    Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, Ross SA.
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381
    [Abstract] [Full Text] [Related]

  • 20. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G.
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.